Diseases & Conditions Articles
Featured Articles
Read our latest stories on the people and scientific innovations making a difference in patients’ lives.
August Social Media Round-Up—Q2 Results, AI Adoption, and More
Summer is coming to an end, but here at Pfizer, the work doesn’t stop when the seasons change. Before we say goodbye to the warmer weather, let’s take a look back at the month on Pfizer’s social media.In August, we highlighted the importance of our manufacturing systems, leveraged a new AI tool in our supply chain, and released a new episode of "What's In My Lab."Meanwhile, CEO Albert Bourla shared our second quarter results, shared how Pfizer is taking on AI adoption, and sat down with TIME...
A Return to Munich: Reflecting on Eight Years of Progress in ATTR-CM
Eight years ago, few people had heard of transthyretin amyloid cardiomyopathy (ATTR-CM), and it was rarely diagnosed in cardiology practice.1,2 Today, it is a treatable condition that cardiologists and heart failure specialists actively screen for, with dedicated clinics, imaging pathways, and a growing evidence base.ATTR-CM is a rare and underdiagnosed cause of heart failure characterized by the abnormal buildup of misfolded transthyretin (TTR) protein depositing in the heart.1 For years, it...
Listening to the Hemophilia Community: Pfizer Survey Reveals Unspoken Compromises
When living with a lifelong condition like hemophilia, decisions about care and treatment are rarely simple. They are shaped by confidence in a treatment’s potential benefits and risks, along with personal experience, familiar routines, and how well it may fit into daily life.Hemophilia is a rare genetic bleeding disorder that affects the body’s ability to form blood clots due to missing or deficient clotting proteins in the blood known as clotting factors. Over the past several decades...
July Social Media Round-Up—America 250, Pfizer Futures, and More
Even amidst the cookouts, fireworks, and vacations, Pfizer remains hard at work all summer long, and July was no different.Last month, we held important conversations around living with alopecia areata, shared the story of a Pfizer colleague and cancer survivor, and reflected on the changes in science over the years.CEO Albert Bourla celebrated America’s 250th birthday, shared advice for our outgoing Pfizer Futures class, and congratulated the World Cup winners. While our leadership team shared...
Exploring the Latest Advances in Menstrual Migraine Research
For millions of people who menstruate, migraine attacks don’t always strike at random. For many, they’re more likely to occur in and around the days of the menstrual period, driven in part by the hormonal shifts of the cycle. When migraine attacks consistently occur on or around menstruation, the pattern has a name—menstrual migraine—and it’s more than just a bad headache.Research suggests migraine attacks that occur during the menstrual period are often more disabling relative to those that...
Menstrual Migraine Explained: Why They Happen and What Can Help
For some people, migraine attacks aren’t random. Instead, they follow predictable hormonal rhythms that unfold over time. Menstrual migraine is a common type of migraine, yet it’s still a condition many aren’t familiar with.1Compared with other types of migraine, menstrual-related migraine may cause more severe symptoms.1 Understanding how and why these migraine attacks occur can help you anticipate symptoms before they begin and work with your doctor to better manage them.Understanding...
May Social Media Round-Up—ASCO, Q1 2026 Results, and More
Summer’s approaching fast, but here at Pfizer the work doesn’t stop. So before you get outside to enjoy the warmer weather, catch up with the latest activity on our social channels.May has been chock full of highlights—from sharing the latest data across our cancer work at ASCO 2026 to a feature in TIME highlighting how we bring science from the lab to life, we’re offering looks behind the science of Pfizer’s research. Next, review Pfizer’s first quarter results, courtesy of CEO Albert Bourla...
Spotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection
For many people living with transthyretin amyloid cardiomyopathy (ATTR‑CM) – a rare and underdiagnosed cause of heart failure – receiving an accurate diagnosis can be a long and uncertain journey.1,2 Symptoms often resemble more common heart conditions, and early clues are easy to miss.1 But, new real-world evidence being shared at the American College of Cardiology (ACC) Scientific Sessions highlights opportunities to raise suspicion earlier in the diagnostic journey.“Many patients are already...
Hiding in Plain Sight: The Racial Toll of Lyme Disease
Lyme disease is the most common vector-borne illness in the United States.1 Caused by the bacteria Borrelia burgdorferi sensu lato and spread through infected tick bites, it affects an estimated 476,000 Americans each year.1,3Yet the burden of Lyme disease, particularly the experience of a timely diagnosis, isn’t shared equally.Despite its prevalence, the face of Lyme disease in public health data is overwhelmingly white. In the United States, surveillance data shows that over 90% of Lyme...
Pursuing the Next Breakthrough in Cancer Cachexia
Cachexia, a complex wasting syndrome, impacts an estimated 9 million people worldwide.[i] In people living with cancer, cachexia can diminish the tolerance of therapies and is linked to reduced survival rates. Currently, there are no FDA-approved treatments targeting its underlying cause.Over time, the way researchers and physicians understand cachexia has evolved, with growing focus on uncovering the biology behind this devastating disease.In an effort to address a critical gap in care and help...
October Social Media Round-Up—Values Day, ESMO 2025, and More
It may be spooky season, but there’s nothing scary about Pfizer’s updates this month. Check out our social media channels to see the latest.Over on our corporate channels we shared highlights from ESMO 2025, spotlighted the personal stories of our Pfizer colleagues and partners, and launched new episodes of “What’s In My Lab” and “The Power of Knowing.”Meanwhile, CEO Albert Bourla announced Pfizer’s voluntary agreement with the U.S. government to lower drug costs for American patients...
Developing a Path Forward in Cancer Cachexia
Across disciplines, therapeutic areas, and even continents, Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia, a complex metabolic condition associated with certain chronic conditions, such as cancer, and characterized by severe weight loss, decreased appetite, fatigue, and muscle wasting. Its symptoms can often be misattributed, and there are currently no FDA-approved treatments targeting its root cause.But, over the past decade, the...
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits. However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer Media Contacts may only respond to calls and emails from professional journalists.